Blue Cross Blue Shield of Michigan will drop coverage of Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) GLP-1 obesity drugs in fully insured large group commercial plans starting in January citing consideration of their “efficacy, safety and access, and cost,” a spokesperson told Bloomberg, reports Ike Swetlitz, Madison Muller and Gerry Smith. Blue Cross Blue Shield didn’t immediately respond to questions about how many patients will be affected or what the potential safety concerns were, the journalists add.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- FDA AdCom on Eli Lilly’s donanemab better than anticipated, says Cantor
- Eli Lilly Stock (LLY) Gained on FDA Panel Approval
- FDA panel votes 11-0 Eli Lilly Alzheimer’s drug benefits outweigh risks
- FDA panel votes 11-0 Eli Lilly drug efficacious in Alzheimer’s, Bloomberg says
- Eli Lilly announces detailed results from Phase 2 SYNERGY-NASH trial